Kura Oncology Announces Oversubscribed $150 Million Private Placement
– Funding from existing investors, including EcoR1 Capital, an affiliate of Deerfield Management and Suvretta Capital –
– Pro forma cash, cash equivalents and investments expected to provide runway into 2027 –
Related news for (KURA)
- Kura Oncology and Kyowa Kirin Report Positive Updated Combination Data for Ziftomenib in Newly Diagnosed AML at 2025 European Hematology Association Congress
- Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data at 2025 ASCO Annual Meeting
- 24/7 Market News Snapshot 02 June, 2025 – Kura Oncology, Inc. (NASDAQ:KURA)
- Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AML
- Kura Oncology and Kyowa Kirin Announce Pivotal Monotherapy Data for Ziftomenib in Oral Presentation at the 2025 ASCO Annual Meeting